Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

BridgeBio Pharma Q3 2026 Results: Net Loss of $56.7M, Loss Narrows

BridgeBio Pharma reported a significant increase in total revenues to $791.4 million for the first nine months of 2026, driven primarily by net product revenue from Attruby and Beyonttra. Despite the revenue growth, the company maintained a net loss of $382.9 million due to high research and development and selling expenses, though this was an improvement from the $538.3 million loss in the prior year period.

Watch the BridgeBio Pharma, Inc. earnings callFull call on the ALFA USA YouTube channel
Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue353.2120.7
Profit before tax-59.3-186.5
Net income-56.7-182.7
EPS (diluted, $ a share)$-0.42$-0.95

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+192.6%
Operating margin-3.3%
Source

10-Q filed with the SEC, NASDAQ: BBIO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

BridgeBio Pharma, Inc.: key numbers

Share price
$77.36Close, Nov 16
Market cap
$15.1B
Shares outstanding
194.8MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from BridgeBio Pharma, Inc.

All →
4:15 PM ET Form 4
Insider Selling

BridgeBio Pharma CAO Maricel Apuli Sells $146K of Stock

Maricel Apuli, CAO, sold 2,000 shares of BridgeBio Pharma, Inc. at $72.85 a share, worth $146K in total on Oct 30, 2026. Shares held after the trade: 120,687 (-1.6%).

Value
$146K
Shares
2,000
Price
$72.85
Role
CAO
Holding change
-1.6%
Trade date
Oct 30, 2026
4:03 PM ET 8-K
Financial Results

BridgeBio Pharma Financial Results

BridgeBio Pharma reported Q3 2026 financial results, highlighted by $353.2 million in total revenue, including $253.2 million from U.S. Attruby net product sales. The company is preparing for three potential product launches in 2026 and 2027 for BBP-418, oral infigratinib, and encaleret, all of which have been granted Priority Review by the FDA.

Term
Q3 2026
6:03 AM ET 8-K
Business Update

BridgeBio Pharma Business Update

BridgeBio Pharma announced that the FDA has accepted its New Drug Application (NDA) for oral infigratinib for the treatment of children with achondroplasia and granted it Priority Review. The FDA has assigned a PDUFA target action date of February 4, 2027, for the potential approval of what would be the first oral therapy for this condition. The filing is supported by Phase 3 PROPEL 3 data showing significant improvements in annualized height velocity and body proportionality.

Counterparty
FDA
6:21 PM ET Form 4
Insider Selling

BridgeBio Pharma CEO Neil Kumar Sells $691K of Stock

Neil Kumar, CEO, sold 10,000 shares of BridgeBio Pharma, Inc. at $69.01 to $69.57 a share (average $69.08) in 2 transactions, worth $691K in total on Sep 17, 2026. Shares held after the trade: 495,686 (-0.3%).

Value
$691K
Shares
10,000
Average price
$69.08
Role
CEO
Holding change
-0.3%
Trade date
Sep 17, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.